An observational study on host immunity in patients with refractory Mycobacterium avium complex pulmonary disease
- Conditions
- Mycobacterium avium complex pulmonary disease
- Registration Number
- JPRN-UMIN000043426
- Lead Sponsor
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Not provided
-Patients with multiple detections of mycobacteria other than MAC. -Patients with macrolide-resistant MAC detected. -Patients whose therapy was discontinued due to adverse events, drug interaction, etc. -Patients who have been treated for less than 12 months. (If the MAC detected is macrolide susceptible, this criterion is not required.) -Patients within 1 year of completing prior treatment for MAC-PD. -Patients who underwent surgery for MAC-PD within 1 year. -Patients within 1 months of recovery from an acute infection. -Patients with chronic liver damage due to HBV or HCV. -HIV-positive patients. -Patients previously treated with immune checkpoint inhibitors for malignant tumors. -Patients with active hematologic malignancies. -Patients after blood stem cell transplants, including bone marrow transplants. -Patients treated for co-morbidities with high-dose glucocorticoid or immunosuppressive drugs. -Super-elderly people over 90 years old. -Pregnant women.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Clinical outcome Treatment failure of MAC-PD under the standard treatment. 2) Immunological outcome Host immune characteristics in treatment failure of MAC-PD under standard treatment.
- Secondary Outcome Measures
Name Time Method